

## Request for Prior Authorization GRANULOCYTE COLONY STIMULATING FACTOR

**FAX Completed Form To**1 (877) 733-3195

Provider Help Desk 1 (844) 236-1464

(PLEASE PRINT – ACCURACY IS IMPORTANT)

	·	
IA Medicaid Member ID #	Patient name	DOB
Patient address		
Provider NPI	Prescriber name	Phone
Prescriber address		Fax
Pharmacy name	Address	Phone
Prescriber must complete all informa	lation above. It must be legible, correct, and c	complete or form will be returned.
Pharmacy NPI	Pharmacy fax	NDC
Prior authorization is required for therapy with granulocyte colony stimulating factor agents. Payment for non-preferred granulocyte colony stimulating factor agents will be authorized only for cases in which there is documentation of previous trial(s) and therapy failure with a preferred agent(s). Laboratory values for complete blood and platelet count must be obtained as directed by the manufacturer's instructions. Dosage reduction and discontinuation of therapy may be required based on the manufacturer's guidelines.    Preferred		
☐ Releuko		
Releako		
Strength	Dosage Instructions	Quantity Days Supply
Strength  Diagnosis (or indication for the pro Prevention or treatment of febri Treatment of neutropenia in pat Mobilization of progenitor cells i chemotherapy. Treatment of congenital, cyclic, of On current chemotherapy drug(	duct): le neutropenia in patients with malignancies who are	e receiving myelosuppressive anticancer therapy. emotherapy followed by a bone marrow transplant.
Strength  Diagnosis (or indication for the pro Prevention or treatment of febri Treatment of neutropenia in pat Mobilization of progenitor cells i chemotherapy. Treatment of congenital, cyclic, of On current chemotherapy drug( Other condition specify)	duct):  le neutropenia in patients with malignancies who are ients with malignancies undergoing myeloablative chanto the peripheral blood stream for leukapheresis cor idiopathic neutropenia in symptomatic patients.  s) that would cause severe neutropenia (specify)	e receiving myelosuppressive anticancer therapy. emotherapy followed by a bone marrow transplant.
Strength  Diagnosis (or indication for the pro Prevention or treatment of febri Treatment of neutropenia in pat Mobilization of progenitor cells i chemotherapy. Treatment of congenital, cyclic, o On current chemotherapy drug( Other condition specify)  Absolute Neutrophil Count (ANC):	duct):  le neutropenia in patients with malignancies who are ients with malignancies undergoing myeloablative chanto the peripheral blood stream for leukapheresis cor idiopathic neutropenia in symptomatic patients.  s) that would cause severe neutropenia (specify)	e receiving myelosuppressive anticancer therapy. emotherapy followed by a bone marrow transplant. ollections to be used after myeloablative
Diagnosis (or indication for the pro Prevention or treatment of febri Treatment of neutropenia in pat Mobilization of progenitor cells i chemotherapy. Treatment of congenital, cyclic, of On current chemotherapy drug( Other condition specify)  Absolute Neutrophil Count (ANC): Dates of routine CBC:	duct):  le neutropenia in patients with malignancies who are ients with malignancies undergoing myeloablative chinto the peripheral blood stream for leukapheresis cor idiopathic neutropenia in symptomatic patients.  s) that would cause severe neutropenia (specify)	e receiving myelosuppressive anticancer therapy. emotherapy followed by a bone marrow transplant. ollections to be used after myeloablative
Diagnosis (or indication for the pro Prevention or treatment of febri Treatment of neutropenia in pat Mobilization of progenitor cells i chemotherapy. Treatment of congenital, cyclic, of On current chemotherapy drug( Other condition specify)  Absolute Neutrophil Count (ANC): Dates of routine CBC:	duct):  le neutropenia in patients with malignancies who are ients with malignancies undergoing myeloablative chinto the peripheral blood stream for leukapheresis cor idiopathic neutropenia in symptomatic patients.  s) that would cause severe neutropenia (specify)	e receiving myelosuppressive anticancer therapy. emotherapy followed by a bone marrow transplant. ollections to be used after myeloablative
Diagnosis (or indication for the pro Prevention or treatment of febri Treatment of neutropenia in pat Mobilization of progenitor cells i chemotherapy. Treatment of congenital, cyclic, o On current chemotherapy drug( Other condition specify)  Absolute Neutrophil Count (ANC): Dates of routine CBC: Platelet Counts: Pertinent Lab data:	duct):  le neutropenia in patients with malignancies who are ients with malignancies undergoing myeloablative chanto the peripheral blood stream for leukapheresis cor idiopathic neutropenia in symptomatic patients.  s) that would cause severe neutropenia (specify)	e receiving myelosuppressive anticancer therapy. emotherapy followed by a bone marrow transplant. ollections to be used after myeloablative
Diagnosis (or indication for the pro Prevention or treatment of febri Treatment of neutropenia in pat Mobilization of progenitor cells i chemotherapy. Treatment of congenital, cyclic, o On current chemotherapy drug( Other condition specify)  Absolute Neutrophil Count (ANC): Dates of routine CBC: Platelet Counts: Pertinent Lab data: Previous therapy (include drug name, see	duct):  le neutropenia in patients with malignancies who are ients with malignancies undergoing myeloablative chinto the peripheral blood stream for leukapheresis cor idiopathic neutropenia in symptomatic patients.  s) that would cause severe neutropenia (specify)	e receiving myelosuppressive anticancer therapy. emotherapy followed by a bone marrow transplant. ollections to be used after myeloablative
Diagnosis (or indication for the pro Prevention or treatment of febri Treatment of neutropenia in pat Mobilization of progenitor cells i chemotherapy. Treatment of congenital, cyclic, o On current chemotherapy drug( Other condition specify)  Absolute Neutrophil Count (ANC): Dates of routine CBC: Platelet Counts: Pertinent Lab data: Previous therapy (include drug name, see as on for use of Non-Preferred drug	duct):  le neutropenia in patients with malignancies who are ients with malignancies undergoing myeloablative chinto the peripheral blood stream for leukapheresis cor idiopathic neutropenia in symptomatic patients.  s) that would cause severe neutropenia (specify)	e receiving myelosuppressive anticancer therapy. emotherapy followed by a bone marrow transplant. ollections to be used after myeloablative
Diagnosis (or indication for the pro Prevention or treatment of febri Treatment of neutropenia in pat Mobilization of progenitor cells i chemotherapy. Treatment of congenital, cyclic, o On current chemotherapy drug( Other condition specify)  Absolute Neutrophil Count (ANC): Dates of routine CBC: Platelet Counts: Pertinent Lab data: Previous therapy (include drug name, see as on for use of Non-Preferred drug	duct):  le neutropenia in patients with malignancies who are ients with malignancies undergoing myeloablative chanto the peripheral blood stream for leukapheresis cor idiopathic neutropenia in symptomatic patients.  s) that would cause severe neutropenia (specify)	e receiving myelosuppressive anticancer therapy. emotherapy followed by a bone marrow transplant. ollections to be used after myeloablative

**IMPORTANT NOTE:** In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Health and Human Services, that the member continues to be eligible for Medicaid.